Ezetimibe ameliorates early diabetic nephropathy in db/db mice

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 7, 2012, Pages 608-618

  Tamura, Yukinori ^a   Murayama, Toshinori ^a   Minami, Manabu ^a   Matsubara, Takeshi ^a   Yokode, Masayuki ^a   Arai, Hidenori ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Albuminuria; Diabetic nephropathy; Ezetimibe

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; CREATININE; EZETIMIBE; GLUCOSE; INSULIN;

ADIPOSE TISSUE; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; FOOD INTAKE; GLOMERULAR STRUCTURE; GLUCOSE BLOOD LEVEL; HYPOADIPONECTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY HYPERTROPHY; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENAL PROTECTION; TREATMENT DURATION; URINARY EXCRETION; WEIGHT GAIN;

ADIPONECTIN; ADIPOSITY; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; CREATININE; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; INFLAMMATION; KIDNEY FUNCTION TESTS; LIPID METABOLISM; MALE; METABOLISM, INBORN ERRORS; MICE; MICE, OBESE; OBESITY; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADIPONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84864525874     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.11312     Document Type: Article

References (28)

1. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest, 1984; 74: 1143-1155
2. Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, Nakano T, Iehara N, Fukatsu A, Kita T, Doi T: Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem, 2003; 278: 18229-18234
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Egg-ers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA, 2007; 298: 2038-2047
4. Yokoyama H, Sone H, Saito K, Yamada D, Honjo J, Haneda M: Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes - interrelations with arterial thickness and stiffness. J Atheroscler Thromb, 2011; 18: 744-752
5. Kim KJ, Lee BW, Kim HM, Shin JY, Kang ES, Cha BS, Lee EJ, Lim SK, Lee HC: Associations between cardio-ankle vascular index and microvascular complications in type 2 diabetes mellitus patients. J Atheroscler Thromb, 2011; 18: 328-336
6. Kwan BC, Beddhu S, Kronenberg F, Cheung AK: Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nat Clin Pract Nephrol, 2006; 2: 76-77
7. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R: Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int, 2006; 70: 177-186
8. Sharp Collaborative G: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J, 2010; 160: 785-794 e710
9. Rizzo M, Rini GB, Spinas GA, Berneis K: The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis, 2009; 204: 330-333
10. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun M P, Crona JH, Davis HR Jr, Dean DC, Det-mers PA, Graziano M P, Hughes M, Macintyre DE, Ogawa A, O'Neill K A, Iyer S P, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A, 2005; 102: 8132-8137
11. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Adachi H, Okuda S, Yamagishi S: Ezet-imibe decreases serum levels of asymmetric dimethylargi-nine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res, 2009; 60: 525-528
12. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F: A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant, 2006; 6: 770-774
13. Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, Ariyasu H, Akamizu T, Kita T, Yokode M, Arai H: Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol, 2008; 28: 2195-2201
14. Dronavalli S, Duka I, Bakris GL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab, 2008; 4: 444-452
15. Nomura M, Ishii H, Kawakami A, Yoshida M: Inhibition of Hepatic Neiman-Pick C1-Like 1 Improves Hepatic Insulin Resistance. Am J Physiol Endocrinol Metab, 2009
16. Jauregui A, Mintz DH, Mundel P, Fornoni A: Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens, 2009; 18: 539-545
17. Tesauro M, Canale M P, Rodia G, Di Daniele N, Lauro D, Scuteri A, Cardillo C: Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract, 2011; 2011: 653182
18. Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol, 2010; 314: 1-16
19. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol, 2003; 284: F1138-1144
20. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saou-gos V, Tselepis AD, Mikhailidis D P, Elisaf M: Effect of ezetimibe monotherapy on the concentration of lipopro-tein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin, 2007; 23: 1169-1176
21. Ix JH, Sharma K: Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol, 2010; 21: 406-412
22. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, Ito T, Funahashi T: Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol, 2007; 27: 1910-1917
23. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J: Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponec-tin. Nephrol Dial Transplant, 2008; 23: 1621-1627
24. Guo Z, Zhao Z: Effect of N-acetylcysteine on plasma adi-ponectin and renal adiponectin receptors in streptozoto-cin-induced diabetic rats. Eur J Pharmacol, 2007; 558: 208-213
25. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARgamma ligands increase expression and plasma concentrations of adipo-nectin, an adipose-derived protein. Diabetes, 2001; 50: 2094-2099
26. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA: Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin, 2005; 21: 333-338
27. Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM: Safety and efficacy of ezetimibe/simvastatin combination versus ator-vastatin alone in adults >/=65 years of age with hypercho-lesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Car-diol, 2010; 106: 1255-1263
28. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Hold-aas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Peder-sen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192